BridgeBio Pharma, Inc. (BBIO): Operating Cash Flow
-$445.91M
Year ended 2025-12-31
-$434.37M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$445.91M | n/m | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | -$520.73M | n/m | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | -$527.72M | n/m | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | -$419.49M | n/m | 2025-02-20, From 2022-01-01 |
| 2021-12-31 | -$497.93M | n/m | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | -$399.71M | n/m | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | -$253.59M | n/m | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | -$136.64M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | -$40.49M | n/a | 2020-03-03, From 2017-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | -$445.91M | n/m |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $37.78M | n/m |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $55.83M | +440.7% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $35.32M | +39.6% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | -$64.66M | n/m |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | -$150.79M | n/m |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | -$10.31M | n/m |
| Insmed Inc (INSM) | 2025-12-31 | -$935.01M | n/m |
| Opko Health, Inc. (OPK) | 2025-12-31 | -$178.54M | n/m |
Compare BBIO, TVTX, MIRM, NATR side by side · Screen every company in Pharmaceutical Preparations ↗